<SEC-DOCUMENT>0001193125-13-446908.txt : 20131119
<SEC-HEADER>0001193125-13-446908.hdr.sgml : 20131119
<ACCEPTANCE-DATETIME>20131119161134
ACCESSION NUMBER:		0001193125-13-446908
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131113
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131119
DATE AS OF CHANGE:		20131119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPLIGEN CORP
		CENTRAL INDEX KEY:			0000730272
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				042729386
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-14656
		FILM NUMBER:		131230108

	BUSINESS ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
		BUSINESS PHONE:		7814499560

	MAIL ADDRESS:	
		STREET 1:		41 SEYON STREET
		STREET 2:		BUILDING 1, SUITE 100
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02453
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d630422d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of
Report (Date of earliest event reported): November&nbsp;13, 2013 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Repligen
Corporation </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>0-14656</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-2729386</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or Other Jurisdiction<BR>of Incorporation)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(IRS Employer<BR>Identification No.)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>41 Seyon Street, Bldg. 1, Suite 100, Waltham, MA 02453 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(781) 250-0111 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><U></U>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see </I>General Instruction A.2. below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.02.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;13, 2013, Earl Webb Henry, M.D., informed the Board of Directors (&#147;Board&#148;) of Repligen Corporation (the &#147;Company&#148;) that he
was resigning from his position as a member of the Board as of December&nbsp;31, 2013. Dr.&nbsp;Henry&#146;s resignation is not the result of any disagreement with the Board or with the Company&#146;s management. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;15, 2013, John G. Cox was elected to the Board. Mr.&nbsp;Cox currently serves as the Executive Vice President of Pharmaceutical
Operations&nbsp;&amp; Technology for Biogen Idec Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Cox will receive cash and equity compensation pursuant to the Company&#146;s non-employee
director compensation policy as set forth in the Company&#146;s Amended and Restated Director Compensation Policy (the &#147;Director Compensation Policy&#148;). Pursuant to the terms of the Director Compensation Policy, Mr.&nbsp;Cox received an
option to purchase 24,000 shares of Common Stock on the date he joined the Board (the &#147;Initial Board Option&#148;). The Initial Board Option vests equally over a three-year period from the date of grant. The Initial Board Option has a term of
ten years, subject to early termination in the event of death, removal or resignation from the Board. The Initial Board Option has an exercise price equal to the fair market value of the stock on the date the Initial Board Option is granted. In
addition, under the Director Compensation Policy, each non-employee director receives an annual retainer for service on the Board and committees of the Board, and except in the year following a non-employee director&#146;s first election to the
Board by the stockholders, each non-employee director reelected to the Board by the stockholders is awarded annually restricted stock units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with Mr.&nbsp;Cox&#146;s appointment to the Board, he has been named to the Audit Committee of the Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no arrangements or
understandings between Mr.&nbsp;Cox and any other persons pursuant to which Mr.&nbsp;Cox was selected as a director. There have been no transactions since the beginning of the Company&#146;s last fiscal year, or any currently proposed transaction,
in which the Company was or is to be a participant, in which the amount involved exceeds $120,000, and in which Mr.&nbsp;Cox had, or will have, a direct or indirect material interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has issued a press release announcing Mr.&nbsp;Cox&#146;s election to the Board, and Dr.&nbsp;Henry&#146;s resignation from the Board, and has
attached a copy of such press release as Exhibit 99.1 hereto. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"><I>Exhibits.</I> </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Press Release by Repligen Corporation, November&nbsp;19, 2013.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3">REPLIGEN CORPORATION</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: November&nbsp;19, 2013</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Walter C. Herlihy</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Walter C. Herlihy</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">President and Chief Executive Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>No.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman"><B>Exhibit</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release by Repligen Corporation, dated November 19, 2013</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d630422dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g630422ex99_1pg001.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP>Repligen Corporation</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">41 Seyon Street</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Building #1, Suite
100</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, Massachusetts 02453</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Telephone: (781)
250-0111</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Telefax: (781) 250-0115</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Repligen Appoints Biogen Idec Executive John G. Cox to Board of Directors </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALTHAM, MA &#150; November&nbsp;19, 2013</B> &#150; Repligen Corporation today announced that it has elected to its Board of Directors John G. Cox,
Executive Vice President of Pharmaceutical Operations&nbsp;&amp; Technology for Biogen Idec Inc., a leading biopharmaceutical company. Mr.&nbsp;Cox has over 20 years of biopharmaceutical manufacturing experience and has supported the commercial
launches of a number of major biologic drugs. He has a track record of implementing process changes to maximize manufacturing flexibility and throughput; this includes playing a leading role in creating the vision for Biogen Idec&#146;s &#147;Future
Factory,&#148; which aims to utilize disposable technology platforms. Separately, the Company announced that at year end, Earl Henry, M.D. will retire from the Repligen Board position that he has held since 2007<B></B><I>. </I><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Mr. Cox&#146;s experience and his perspective as an end user of the products developed and marketed by Repligen make him ideally suited to provide
strategic guidance to our Company, and we are pleased to welcome him as an important addition to our Board,&#148; said Walter C. Herlihy, Ph.D., President and Chief Executive Officer of Repligen. &#147;We also sincerely thank Dr.&nbsp;Henry for his
many contributions to Repligen; in particular, his medical expertise was invaluable while the Company was active in the clinical development of therapeutics.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Cox joined Biogen Idec in 2003 and has held multiple roles of increasing responsibility in the areas of manufacturing and technical operations.
Mr.&nbsp;Cox has served as Executive Vice President of Pharmaceutical Operations&nbsp;&amp; Technology since June 2010. He has also served as Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, Vice
President of Manufacturing, General Manager of Biogen Idec&#146;s operations in Research Triangle Park, North Carolina, and Director of Manufacturing. From 2000 to 2003, Mr.&nbsp;Cox held a number of senior operational roles at Covance Biotech (a
contract research organization acquired by Diosynth) where he worked in technology transfer, validation and purification. From 1993 to 2000, he focused on the same areas at American Home Products Corporation, now the Wyeth, LLC subsidiary of Pfizer
Inc. Mr.&nbsp;Cox received a Bachelors of Science degree in biology from Arizona State University, a Masters of Science degree in cell biology from California State University and a Masters of Business Administration in finance degree from the
University of Michigan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">- more - </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Repligen Appoints Biogen Idec Executive John G. Cox to Board of Directors </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I> Page
 2
 of 2 </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>November 19, 2013 </I></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Repligen Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development, production and commercialization of high-value consumable products
used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are a leading manufacturer of Protein A, a critical reagent used to separate and purify
monoclonal antibody therapeutics. We also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, we have developed and market our OPUS<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> line of pre-packed &#147;plug-and-play&#148; chromatography columns, and we provide test kits to ensure final product quality. Repligen&#146;s corporate headquarters are in Waltham, MA (USA) and
our manufacturing facilities are located in Waltham, MA and Lund, Sweden. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release may contain forward-looking statements within the meaning
of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like &#147;believe,&#148; &#147;expect,&#148;
&#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;seek,&#148; or &#147;could&#148; and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.</I> <I> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Repligen Corporation </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sondra Newman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(781) 419-1881 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>snewman@repligen.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Source: Repligen Corporation </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g630422ex99_1pg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g630422ex99_1pg001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`)P":`P$1``(1`0,1`?_$`&L```(#`0$!````````
M```````*!P@)!@L$`0$`````````````````````$```!@(!!0`"`@$#!0``
M```"`P0%!@<!"`D`$1(3"A05(2(602,D,7$R)A<1`0``````````````````
M``#_V@`,`P$``A$#$0`_`'^.@5XYJ/I(;>)+9^$ZRLFKR?89[D%/,=JR1Y,N
M`RN<1<R22B5L#-',-Q5<3;+@I.1142T9N3B?$M25C`,]_+H,A3/N#D)(!&&\
M:!10`]O(9FSZX``]\X#CR$*@,8QW%GM_WZ#>/AM^B?73EPFLFI(FKI1KOL1&
MHJJG":OI%)6Z;QJ:Q-L5(4#XXPJ;(FF-G*W-B4.)!BMN6-B0\*8W!Q`E)92@
M1(,/=`=`=`=`=`M+6GT(K[BYHG[B5KO5-,]-$6M*QZY?]A!7$,'X":I(*^2>
M=OHZ]*K<TKL@D$<5-))/[K_<,]8\C#D62\!SW(K]`=E:A\I=-<:5*ZMQB[GJ
MS%-!1QWF[W8,@C2F.36])<)H1LX61IA[VG4(F6,.#8Y#/&I!D6%8PB"`)?D(
M-]]I=J:$TNI&9[$;*6(S5E5$%2`.=W]VR<>I6KU0LE-<=CC.B+4.TEE+XIQZ
M43<B).5*3/\`Q!XA$((+0IN>[E,V]*63GB\X8+'M#7P)ZG$8NO8:5E0)/8B%
M,H$`3I&6$3C$(^-.,O&,8"WR)]R$><A%D(PB!@)OT*^B-RM7;ABX^.1G3V=\
M?^W4O/2M]>(Y(M<7*O+">7(L\UB9DQ[ZS,CO'5<M_&,*8U`#'=H=U(/QREP%
M`R"309SZ`Z`Z`Z`Z`Z`Z#RQ]T;]I&^/JS5V#L38\0@>NM$;;5Y%9/+IHKR7#
M6>/:CL#2%T:'(\LI6$:64V)7RM)@&`"`:H<O$7]19ST#JMR\]'!C#*QF<@?-
MIJ`M5M2L+G@^MX1%S;`DLX]B0[`8NW1<N-&HUQKV+_C]UPR&\/L[J#BBO(>`
M55^3'2ZPK!WLN+DW<X";3>J=7QJXFV`N3B48RQ1SEME*#DYD2B:U=A(D=(I5
ML`4KLNBT&<ID1WX18L^8Q^L+@W?SP\K7*IMM/]3.!V`M<>K.M,.ACML"\,D)
M6R&4,#>OPTYL%UD%M$JJ\K"$/S@6(+"@RA42%Q*S@WR"8(Q&E"%-4^;CF4X[
M^3FL-#>71V16=%K+FU=0J0X?&*L02&(-%O.J-BAELUW8M4-3*V2B-(G98`:]
M,NPOP).G5I@A2K2L^L+Y?3ES@;C<<&QVM=`Z:6/&H&Y22H'RT[8&[5U"+$6+
MT\BFBB*0,A.3,6IT"UB0XA3R9X$>G*G\D/GG.``[!0[D`WX^JELIPW?=OKMX
MTUT[8DD>=T$2CS!K_);"C\2<QM[<RSBZXO*FV3V:0HD"M02:X@$V-;:WF*L8
M$@2$X\N@8'X">965\C6@]NW/LREC[/<&I[P],US2.,MY;)'IA$T$-%.6*Q2F
M0H0D<?<G!I1KTS@D3]DF%3<,\@!))X$Y(+:?(E$'?9SE-WHWCEZ4U6O8X!,G
MQ2K.Q[/Q;%VAMDR1#4^\7?NI$P1-])SVSWR`\7^F?Y#0K1OEYWKW:^B>V=28
MY9<.'I55%H;)C5QE-3=5J'Y56]'H'V"QDX%CCBHIV5^ZL<+0H_*PXY-P4I]0
M18+R$.`^Z_VS'.O]#!^FL\-4OG'[Q6,BR86?``J#BXU;%TMZAD:G]LDQ))P0
M*C5T]>BH\:29@6<,$;=0$9)$X'CR#>EEWAKCK!&XJ"X+<I77N(JL%QB$EV+.
MX154=4!9&\K!4?BQ<D=&)M-`T-98,!2I,9PG(P'L$(>W08G;VT3Q*<JFP6DM
M@N/(;2,>O;6&U$#W3I-%["Z\.DTL9_<YC!I%'((N2*UTC?WHHJ51`@38E;L%
MJ0J%ZCU?W.Z"P?+;RP*M`"*8HG7^HSMG=^-KWX<6ULUY0JC4Z([P/"B6V'8B
ME&>F6-T&:5IGK`#!R,2\PH__`)25*D7+4H8\[1*?JRU3H:8[TRK:C2^=,U21
MA?:-JZCP:J&=6W,-?L1(WR4IFY_7URUO\H_Q1F)--7A32HE9^(G-RD6*C`@P
M8&G]F<OIKCP'R/EGK=J98?.'C7/,ABT<>0_OV",7RY2TNFL,0R5(T9LA8F"X
M33"R@F>H:Q$0'(\!R,6,!G-JML#]&O*IJ)4%QT).=9-%H<X0H!@KCMF`ER&S
M]DYA^6L$Z2^'5Z"&3^)UA2Z94'#:TG'I!.KF6D$XA$:0J+*+"TGS[<F>Y^X,
MLWLU%WZ1PQZV+T.M!F@<@LV!L[:QM4OPX/\`8D/>6QU0L"=!&CW!ADE;*#$B
M]`C0%+T"TOS3`,)&8<#+'0<98TY9*PKV>65)3L)XY7D,E$Y?U`A8`$ADB3(N
M?W4[(Q8S@&"D+>8+OG^,=N@\KW@!XUZCYL=W-RYIM^7/%U?L<6>K=?QP.49B
MSNHN&Y[5_9,WYST)O<QFH#&I'(S!$X`$1IP`"R+L#.!!HO\`0A\]_'?QO:##
MV=UT>+LCEE(;?KV`-C'-I\@FD8EZ:8_NC'1O.2*(VWN*!S;FIH.7D*"%6`>*
M099A0_9@986*TZV*V)BWQS;3V')Y;)'UR:FNUZ1J%X7*U"EU8J0EUAP.DE30
MA<LYPMPVQHZ5R-.C%D8LHTY0"2\A*)+``,TOGYXMN0S:75ZT;^T4Y0!Z7-SM
M;Y];6A7D4(E^)`\.T`C;2]QA[E"F+O;=@Q()NL)3AN+.!GPP(_(,Y\Q]@MA"
M.&I=LUR844MV'YYM:MR]FJ5MB$)9-5)SL]3B\UT5H.;J+"F-9($YLR7JFHYE
M3H7?!H3@9*;SS3AFA[X$'(07N58%9[A?7O6T1M9>SJ*CK'9BBJ/3I7\].-C7
M.5-1EM=LQ%P`ISA*:FD=Y@5MXTP^X3Q+,E"QGSSCH&M_ILW!K+6#B;V+A,G?
MVD%E[/QD5$5-"35283Y)5,J7MQ,W>TK:(>5?Z:&0C*U6I6^O)!*K*0@0PFJB
M,"!:/CCBTIT*^5CDFVKE(%<:D&Z2M\A%7E'EF(USA!I;E@UI87I&`WP.P8L>
MI7*%A`\!P$Q$F+/!D0!A%D+T?*>RM^H'#3O;OA)2"$G[>5VU/RE2D(2P+H+K
M#4(EC7C)IG8)P!3%RD!`0XSVR/&0XQWS_(5.^*2GW2;WWOSM])P"7.C9#X-5
M"-\5!]AZ]\MB7/-D3HPLT>!"PH+%7S6,[.!>6<*\=_XS_(7(^91W;XIRG\\E
M7669^MV"=[_62C]8[F@+>76-1F];[2S5>@(-P!0>B1O<V933C`8]8@+TPL?U
MR'/0-";K\:^E?(FCKQOW'I5-<J"J5,E6P%(LFMBQ).PJY@4R$2%2$N`RZ+8<
M#EY,=1A[JO?ZL%9]?AYC\@25UQUJX[)[]1VO5+\;]8QJ,Z[Z61653VUI!%Y?
M-+"8)O=58LDM<5;^T/LUE,I,&UQ"PI+&&(!J0T*0:]M4&E9,",LT039.*GW/
MY"_ITWI6:O;:L6H-J:64K&(?6<_DE3L-S*6R`"C$$B4F8HW%989EK:Q2)]LU
MY7G.`0B&66Y#*!C&%&1=!>+<O2OEPJ_72R#]TOHVJ&M]=9\PN-1V`ZS_`$\J
M.'L;TTV:VKHLNB0'EO4-[P4MD36N4DAPA-`K"5[#`"!@L0PA3SF#H)1I=P+\
M9O$]6]E(K=D^Q^S4!A#+.FAF6QI!83!(YK,[BR[M\:<%SFX(T.9Y8\9`62:>
M(8<>.1>.<X#@';8I'H+KA1D<BK:!,P5K0]4-+"A`66!.D9H16,1(0)_$L.<%
MDD(&)DQ_'?L$(>@6'^2R-.L_U^WRWLE*494IW6WAL.4B4'XR(]7'XL`Q^)-]
MH@]Q%%3.SWXC&,9SC`B,_P#3H&T>@J]NQ0$EVLU(V)UHB-BEU*]WS4TPJ<NQ
M3(\;*\15MG+6='WY>&/$OD:-<S3&%<I)`#"Y-XC-P/R_KVR&8W!KPI-O#5`;
M^C9UY)K^E5\2^&/CC+4];"K4#1'X(RNZ!BCN&PV;3DU<(MQDKDI$?^22'.#P
M@]?<'D(.^YN.)MYY@-<ZQU^;=@B]?$D`N9#;B]Z/KHZR2)&-MA4PB"-G&T$S
M>"Y1C(S+C%`5&5!V,>&0^O\`MY!#O-0.+"#T;Q8-'%E?,E8KZK$$#LZM)5)8
M_#EE7F2B,61,)3+A+_U!DLFJAGF#,LE&1DN)*[.0K$I*DL!8P]N@6(%\=FS]
M0SF7)M2>522U54<U-PE=DXHS84/G*N.X]P4S/+BZTL5EC-@&H"51H/:;AL(.
M\Q9PG)P/(<!OQQ3\'FG_``Q0Z>VRU2!XMZ]W*&.G_P!-V-GS<A:US;"FHO\`
MR!]CT`BZ12X)8)%%1K6!4N#E8O<%YJ<O\A6844244"*/$+QOM//;N%R33>SI
MQ*JS7+HY,+LB%F,)&755![YN6]4LJACB[LQJYO!(F3,>:I$E4H?RDQ@BC/,@
M\DXHHP(;]T9\=LAE5RQ^P^17?J8[-PB)&(R$T#C2.;)Y!+61N/R<DC;Q9<]F
M+\\Q.,G>.`*$C4ERIR4,84ZQ,9XG8#?OEIXE@\C6CU=:+U!;D=U*K.`SRO7\
MDAGJO_-F/,'K**2*/16N6>,-\T@29E:&]8Z(E18\'FA+PVEEX*_MYA#EF'AU
M507A/7<0U<WZDC#D\UL^P!]V#%6ABH#D9.;056%8SN.N"IPC-_\`9FYV7-0"
M1/@LD$GA'DPSP]8@[7A1XEFGA^UEG5#%6T1>,DL.X7FU9#89,%%7N#25<5B<
M598V6P&2R9F83LB>-&'8.RM_W#5IG8L';^0J%R:?/\?M+M*S\@FC&TDJT0W?
M0IT1$HG46;W!7$K),;6PEB1.[V7'W9C>V"1GQX@MN<3P9<4#N@(+*5(!C]AQ
M@0RT\-',_L4@%77()S>35UH5<5A!+Z^U7KQDKF76"PC%@M:P.]DHHS`5+<@=
M4>1%J0J6]Z(.`+(1DCQG.<A>O0'@NUPXY-V[GVMU]<4[%")_K[7E!0&ERXV>
M(ZO4,:(AA\[EKI8KE)'5UF\CLR0P=,Y+3CD:4P"@\_&1FA$#`0@GD"X-K<MG
M=HGDLXY=RG31[<9UC3?$[-4JH@3,JWM9N:VA`P)5C\W>T8$RI2QLK<E<$BUN
M>FQ?AM2*,)B%9(E!H<Y6/!5L3L#==:7SS+[\OV_6*6?R)=5>M<7@#/5.M3-,
M$GIREDLLBC*2V-LX.*R7CR(_3MV5(0X)5G*D8C4@PN_O1Q8J]W]Y>._:V1W:
MGC%<Z#35VLA'2`J_&_"L6;+GV,2%$Z&2\4P:TD<*;E\&:.P!-*\0@$&8P(/L
M_J%^-M*9DNQFK^P=`1">EU;([MIVPJH;;%,81RC_``L5@1=RBJF1%Q\#NP#=
M5#:C=##"BL+4W<W`<^>.W007QAZ+,O&WI#2>G+-,"[#%52.5F/4_+CN8GF92
M*93>1S=X>AQ[+S(1->/R9#^.65E:IR$D@'<>?]`OST!T!T!T!T!T$+[(06&V
MAKU>=;6--5U;5Y/ZAL>&3ZP6Q[9HRX0F$26(.[/+)4DDDB2KF&/'L3`L4*<+
MEA)B9)Z_:8'(09Z#(7@^T@XM-*6'8EFXU]M(QM@*?/%<.=Q/31L%25\NT/"Q
M(I@E@34N/IE`VIHRWN8G%X.3@7%Y&K,+-R6+."18"&\70'0'0'0'0'0'0'0'
)0'0'0'0'0?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
